A5086713425- Cell Adhesion Molecules Research
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Molecular Biology Techniques and Applications
- Cellular Mechanics and Interactions
- Amino Acid Enzymes and Metabolism
- Pain Mechanisms and Treatments
- Immune Cell Function and Interaction
- Alcoholism and Thiamine Deficiency
- Menstrual Health and Disorders
- Acute Lymphoblastic Leukemia research
- Ubiquitin and proteasome pathways
- Monoclonal and Polyclonal Antibodies Research
- Biochemical Acid Research Studies
- Ion Channels and Receptors
- Biochemical and Molecular Research
National Enterprise for NanoScience and NanoTechnology
2021-2025
Italian Institute of Technology
2025
Institute of Oncology Research
2019-2024
Scuola Normale Superiore
2021
Università della Svizzera italiana
2019-2020
University of Modena and Reggio Emilia
2006
Bv8, prokineticin-1 or EG-VEGF (endocrine gland-derived vascular endothelial growth factor), and prokineticin-2, are naturally occurring peptide agonists of two G-protein-coupled receptors (GPCRs), prokineticin receptor 1 (PKR1) PKR2. PKRs expressed in neurons the CNS peripheral nervous system many dorsal root ganglion (DRG) cells expressing also express transient potential vanilloid receptor-1 (TRPV1). Mice lacking pkr1 gene were generated to explore role PKR1 nociceptive signaling...
Abstract Copanlisib is a pan–class I phosphoinositide 3-kinase (PI3K) inhibitor with preferred activity toward PI3Kα and PI3Kδ. Despite the clear overall clinical benefit, number of patients achieving complete remissions single agent relatively low, problem shared by vast majority targeted agents. Here, we searched for novel copanlisib-based combinations. was tested as agent, in combination an additional 17 drugs 26 cell lines derived from mantle lymphoma (MCL), marginal zone (MZL), T-cell...
Hematologic cancers are among the most common in adults and children. Despite significant improvements therapies, many patients still succumb to disease. Therefore, novel therapies needed. The Wiskott-Aldrich syndrome protein (WASp) family regulates actin assembly conjunction with Arp2/3 complex, a ubiquitous nucleation factor. WASp is expressed exclusively hematopoietic cells exists two allosteric conformations: autoinhibited or activated. Here, we describe development of EG-011,...
Introduction: Copanlisib has shown activity in lymphomas, but the number of patients achieving complete remission is relatively low, a problem shared by many targeted agents. We performed pharmacological screening to identify active combinations. Methods: tested copanlisib as single agent and combination with other molecules cell lines derived from mantle lymphoma (MCL), marginal zone (MZL) T lymphomas (T-NHLs). Synergism was evaluated Chou-Talalay index, previously done (Tarantelli et al,...
Abstract Hematological cancers are among the most common in adults and children. Despite significant improvements therapies, many patients still succumb to disease, therefore, novel therapies needed. The Wiskott-Aldrich syndrome protein (WASp) family proteins regulate actin assembly conjunction with Arp2/3 complex, a ubiquitous nucleation factor. WASp is expressed exclusively hematopoietic cells exists two allosteric conformations, auto-inhibited active conformations. Here, we describe...